Table 5 Univariate and multivariate analyses for overall survival and disease-free survival of the 141 rectal patients with clinical LPNM who underwent TME + LPND

Gender: male/female

0.86 (0.37–1.98)

0.85 (0.46–1.56)

Age

1.02 (0.97–1.06)

0.99 (0.97–1.03)

Preoperative treatment

1.70 (0.65–4.48)

1.59 (0.85–3.00)

Preoperative CEA level

1.01 (0.98–1.03)

1.01 (1.00–1.03)

1.01 (0.99–1.02)

Preoperative CA19-9 level

1.00 (0.99–1.01)

1.00 (0.99–1.01)

Histology

2.83 (1.21–6.64)

1.38 (0.55–3.44)

1.77 (0.95–3.29)

Perineural invasion

2.78 (1.19–6.46)

1.48 (0.54–4.09)

2.06 (1.13–3.76)

1.77 (0.86–3.65)

Vascular invasion

1.29 (0.52–3.19)

0.98 (0.50–1.91)

Lymphatic invasion

6.00 (2.42–14.89)

3.34 (1.13–9.88)

2.31 (1.24–4.29)

1.48 (0.70–3.12)

T stage: T3-4/T1-2

2.36 (0.70–8.00)

1.24 (0.61–2.51)

N stage

  N0

Reference

Reference

Reference

Reference

  N1

1.67 (0.51–5.50)

1.08 (0.30–3.89)

1.38 (0.66–2.90)

0.87 (0.38–2.03)

  N2

5.06 (1.74–14.76)

2.68 (0.84–8.54)

2.32 (1.12–4.83)

1.16 (0.48–2.85)

LPN metastasis

4.49 (1.82–11.12)

3.06 (1.15–8.17)

2.95 (1.59–5.50)

2.39 (1.18–4.87)

Mesorectal LN harvested

0.98 (0.93–1.03)

0.99 (0.96–1.03)

LPN harvested

0.99 (0.98–1.01)

1.00 (0.99–1.01)

Adjuvant chemotherapy

0.58 (0.25–1.35)

0.72 (0.39–1.33)

Anastomosis leakage or SSI

1.11 (0.44–3.10)

1.66 (0.23–12.06)